For the past several months, AMRI has been providing development, scale-up and manufacturing services at a number of its global R and D and production sites, demonstrating operational flexibility and expertise to deliver capacity for lipid excipient supply for the vaccine at unprecedented speed to support the program.
This critical lipid excipient surrounds and protects the vaccine's active ingredient.
AMRI, a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries.
AMRI's team provides a suite of solutions in discovery, development, analytical services, and API and drug product manufacturing.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine